Asst Prof Yeo Tianrong

Dr Yeo Tianrong is Head & Senior Consultant, Department of Neurology, NNI@TTSH and Deputy Director, Clinical Research at the National Neuroscience Institute (NNI). He holds a position of Assistant Professor at both Duke-NUS Medical School and Lee Kong Chian School of Medicine. He is also the Deputy Director of Brain Bank Singapore and has joint appointments at the Institute of Molecular and Cell Biology (IMCB A*STAR) as Senior Principal Scientist and at the Duke-NUS Neuroscience and Behavioural Disorders programme.

Dr Yeo’s clinical and research interests are in neuroimmunological diseases. He provides both inpatient and outpatient clinical services, taking care of people with Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorders (NMOSD), Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease (MOGAD), Autoimmune Encephalitis and other immune-mediated diseases of the central nervous system.

Dr Yeo is actively involved in clinical-translational neuroimmunology research. He obtained his DPhil from the University of Oxford in 2020, studying the use of metabolomics in neuroimmunological diseases for biomarker discovery in human cohorts and investigating the metabolic perturbations associated with pathological processes in animal models of neuroinflammation. He was awarded the National Medical Research Council (NMRC) Transition Award in 2021 to study the relationship between the gut microbiome and its derived metabolome with systemic and neuroinflammation MS and NMOSD. In 2025, he was awarded the NMRC Clinician Scientist Award to investigate the molecular underpinnings of cortical pathology and meningeal inflammation in MS using patient-derived samples and animal models via a spatial transcriptomics approach.

Dr Yeo is serving as an Editorial Board member of Scientific Reports and has reviewed for multiple journals and funding bodies. He has lectured and presented at major regional and international MS conferences and is a member of the scientific committee for PACTRIMS (Pan-Asian Committee for the Treatment and Research in Multiple Sclerosis). He is also actively involved in the clinical and research training of medical students and residents, many of whom have won research awards at national and international scientific conferences. Dr Yeo has received several awards in recognition of his contributions to clinical care, research, and education.

• FRCP (Edin), 2022
• PhD (DPhil Oxford), 2020
• MCI (NUS), 2017
• MMED Internal Medicine (NUS), 2012
• MRCP (UK), 2011
• MBBS (NUS), 2007

• Head & Senior Consultant, Department of Neurology, National Neuroscience Institute, Singapore
• Visiting Consultant, Department of Neurology, Changi General Hospital, Singapore
• Assistant Professor, Duke-NUS Medical School
• Assistant Professor, Lee Kong Chian School of Medicine, Nanyang Technological University
• Director, Clinical Research, Neuroscience ACP, SingHealth Duke-NUS Academic Medical Centre
• Deputy Director, Clinical Research, National Neuroscience Institute
• Deputy Director, Brain Bank Singapore
• Senior Principal Scientist, IMCB A*STAR
• Clinical Lecturer (Yong Loo Lin School of Medicine, National University of Singapore)
• Co-lead, NNI Learning Culture Workgroup, 2025 to Present
• Member, Scientific Committee for PACTRIMS (Pan-Asian Committee for the Treatment and Research in Multiple Sclerosis), 2023 to Present
• Member, NNI Tissue Bank Steering Committee 2024 to Present
• Research Lead, NNI Neuroimmunology-Neuroinflammation Programme, 2020 to Present
• Faculty, SingHealth Neurology Residency Program, 2015 to Present
• Member, Clinical Neuroscience Society Singapore, 2012 to Present
• Treasurer, Clinical Neuroscience Society Singapore, 2015 to 2016

• Clinician Scientist Award (NMRC, 2025)
• MOH HMDP Fellowship Award (Team) (MOH, 2025)
• Special Recognition Award (Campus Teachers) (LKC School of Medicine, NTU, 2025)
• Singapore Health Quality Service Award, Star Award (SingHealth, 2024)
• NNI Service Quality Award, Star Award (NNI, 2023)
• COVID-19 Resilience Medal (MOH, 2023)
• TTSH Antimicrobial Stewardship Programme, Antibiotic Guardian Award (TTSH, 2022)
• NNI Service Quality Award, Gold Award (NNI, 2022)
• Singapore Health Quality Service Award, Gold Award (SingHealth, 2022)
• Singapore Health Quality Service Award, Silver Award (SingHealth, 2021)
• Transition Award (NMRC, 2021)
• SingHealth Duke-NUS Neuroscience ACP Research Paper of the Quarter (Jan – Jun 2020)
• Educational Award (MSVirtual, 2020)
• SingHealth Duke-NUS Neuroscience ACP Research Paper of the Quarter (Jul – Dec 2019)
• Long Service Award (10 years) (SingHealth, 2018)
• Educational Travel Award (ACTRIMS, 2019)
• Educational Travel Award (ECTRIMS Summer School, 2019)
• Travel Award (1st Nordic Metabolomics Conference, 2018)
• Research Training Fellowship Award, Overseas PhD (NMRC, 2016)
• Outstanding Tutor Award (Yong Loo Lin School of Medicine, NUS, 2016)
• MCI Research Scholarship Award (NMRC, 2015)
• Best Registrar Award (SingHealth, 2015)

As Principal Investigator:

• Neuroimmunology Longitudinal Singapore (NILONS) Study, NNI
• An animal model of Multiple Sclerosis cortical pathology, NNI and LKCMedicine
• Deciphering the relationship between the gut microbiome and metabolome with systemic and neuroinflammation in Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and related neuroimmunological disorders, NNI
• Evaluating the performance indices of immunoassays and histological tests in the NNI neuromuscular laboratory, NNI
• Longitudinal evaluation of immunogenic responses after COVID-19 vaccination in patients with Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and related neuroinflammatory disorders, NNI
• Validity and reliability of the Fatigue Severity Scale in Multiple Sclerosis and Neuromyelitis Optica/Neuromyelitis Optica Spectrum Disorder population in Singapore (FAMNS), NNI
• Prevalence of Central Nervous System Autoantibodies in Cryptogenic Epilepsy and Insights into Immunotherapy Treatment Effect (PACE), NNI

• Kacerova T, Sealey M, Saldana L, Xiong W, Woodhall M, Waters P, Sénard T, Cheeseman J, Urbanowicz PA, Hunt GE, Spencer DIR, McCullagh JSO, Leite MI, DeLuca G, Palace J, Anthony DC, Yeo T*, Fay Probert. Plasma N-Glycan Profiling Enhances Diagnostic Precision in Multiple Sclerosis, AQP4-Ab NMOSD and MOGAD.  Neurol Neuroimmunol Neuroinflamm 2025 Nov;12(6):e200502.
• Prashaad MH, Siew RWE, Aw AYY, Tan JHY, Yaaseen M, Tye JSN, Prasad K, Tan K, Kuhle J, Chao Y, Ho IAW, Yeo T*. Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies, pro-inflammatory cytokines, NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study. Ther Adv Infect Dis 2025;9:12:20499361251370471. 
• Lau RRL, Tay KSS, Saffari SE, Wong PYW, Lim MT, Koe ASH, Tan JMM, Yong KP, Tan K, Chai JYH, Yeo T*. Impact of the COVID-19 outbreak on the incidence of Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes associated antibodies in Singapore. Brain Behav 2025;15(7):e70630. doi: 10.1002/brb3.70630.
• Yeo T, Bayuangga H, Augusto-Oliveira M, Sealey M, Claridge TDW, Tanner R, Leppert D, Palace J, Kuhle J, Probert F, Anthony DC. Metabolomics detects clinically silent neuroinflammatory lesions earlier than neurofilament-light chain in a focal multiple sclerosis animal model. J Neuroinflammation 2022;19, 252.
• Yeo T, Probert F, Sealey M, Saldana L, Geraldes R, Höeckner S, Schiffer E, Claridge TDW, Leppert D, DeLuca G, Kuhle J, Palace J, Anthony DC. Objective biomarkers for clinical relapse in Multiple Sclerosis: A metabolomics approach. Brain Commun 2021;3(4):fcab240.
• Probert F*, Yeo T*, Zhou Y, Sealey M, Arora S, Palace J, Claridge TDW, Hillenbrand R, Oechtering J, Kuhle J, Leppert D, Anthony DC. Determination of CSF GFAP, CCN5, and vWF levels enhances the diagnostic accuracy of MS from non-MS patients with CSF oligoclonal bands. Front Immunol 2022;12:811351. (*joint first authors)
• Yeo T, Sealey M, Zhou Y, Saldana L, Loveless S, Claridge TDW, Robertson N, DeLuca G, Palace J, Anthony D, Probert F. A blood-based metabolomics test to distinguish relapsing-remitting and secondary progressive multiple sclerosis: addressing practical considerations for clinical application. Sci Rep 2020;10:12381.
• Yeo T*, Probert F*, Jurynczyk M, Sealey M, Cavey A, Claridge TDW, Woodhall M, Waters P, Leite MI, Anthony DC, Palace J. Classifying the antibody-negative NMO syndromes: Clinical, imaging, and metabolomic modelling. Neurol Neuroimmunol Neuroinflamm. 2019 Oct 28;6(6):e626. (*joint first authors)

Refer to Google Scholar for full list of publications: https://scholar.google.com.sg/citations?user=BiAIDdEAAAAJ&hl=en